№ 1 / 2013 / 61-66

Author: Chelysheva E.Yu., Turkina A.G., Polushkina E.S., Shmakov R.G.

A case of a successful pregnancy outcome in a patient with chronic phase of chronic myeloid leukemia has been provided. The need to choose a therapy during pregnancy was the particularity of the case. The increasing of the leukemic cell mass evaluated by quantitative method of real-time polymeraze chain reaction (expression of chimeric oncogene BCR-ABL) has been observed at the moment of pregnancy diagnostics and during further monitoring. Since the 2^nd trimester of pregnancy the patient was treated by imatinib. BCR-ABL transcript level rapidly decreased and a complete molecular remission was achieved at high tolerability. A healthy child was born at the 37^th week of pregnancy. The approaches to therapy tactics of chronic myeloid leukemia during pregnancy have been discussed.

pregnancy, imatinib, chronic myeloid leukemia

1. Lazareva O.V. IT monitoring and analysis of remote results of treatment of patients with chronic myeloid leukemia: abstract of thesis…candidate of medical sciences. Moscow, 2011. (in Russian)

2. Vinogradova O.Y. The clinical evolution of chronic myeloid leukemia during the treatment with tyrosine kinase inhibitors: abstract of thesis…doctor of medical sciences. Moscow, 201. (in Russian)

3. Investigators Brochure, STI 571 (formerly CGP 57148B), and data on file, Novartis Pharma AG, Basel, Switzerland.

4. Hensley M.L., Ford J.M. Imatinib treatment: specific issues related to safety, fertility, and pregnancy // Semin. Hematol. 2003. 40. (2). 21–25.

5. Pye S., Cortes J., Ault P. et al. The effects of imatinib on pregnancy outcome // Blood. 2008. 111. (12). 5505–5508.

6. Mahon F.X., Réa D., Guilhot J. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial // Lancet Oncol. 2010. 11. (11). 1029–1035.

7. Aksenova E.V., Krutov A.A., Soldatova I.N. et al. Molecular monitoring of patients with chronic myeloid leukemia: correlation with cytogenetic response, prognostic value, the estimation of therapy response // Klinicheskaya onkogematologiya. 2010. (2). 151–159.

8. Bayraktar S., Morency B., Escalуn M.P. Suc­ces­sful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester // BMJ Case Reports. 2010. doi:10.1136/bcr. 2975.

9. Conchon M., Sanabani S.S., Bendit I. et al. Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study // J. Hematol. Oncol. 2009. 2. 42.

10. Briggs G.G., Freeman R.K., Yaffe S.J. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. LWW, 2008. 918–921.

11. Polushkina E.S., Shmakov R.G., Khoroshko N.D. et al. Clinical management of pregnancy in women with hematologic malignancies (Part II – myeloproliferative disease) // Klinicheskaya onkogematologiya. 2009. 2. (3). 250–256.

12. Conchon M., Sanabani S.S., Serpa M. et al. Successful pregnancy and delivery in a patient with chronic myeloid leukemia while on Dasatinib therapy // Adv. Hematol. 2010. 1–4.

13. Chelysheva E.Y., Turkina A.G., Kolosheinova T.I. et al. Pregnancy outcomes and treatment regimens in patients with chronic myeloid leukemia // 17^th congress of European Hematology Association. Amsterdam, 2012. Abstract 0766.

14.          Russell M.A., Carpenter M.W., Akhtar M.S. et al. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord, placenta and breast milk // J. Perinatol. 2007. 27. 241–243.

About Authors (Correspondence):